# Intranasal Insulin for COVID-19-related Smell Loss

> **NCT05461365** · PHASE3 · COMPLETED · sponsor: **Universidad Panamericana** · enrollment: 27 (actual)

## Conditions studied

- Anosmia
- Smell Loss
- Paraosmia
- Hyposmia
- COVID-19

## Interventions

- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT05461365
- **Lead sponsor:** Universidad Panamericana
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2021-11-25
- **Final completion:** 2021-12-20
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461365, "Intranasal Insulin for COVID-19-related Smell Loss". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05461365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*